The mechanism of action of Inavolisib in the treatment of breast cancer

Inavolisib (Inavolisib), as a PI3Kδ selective inhibitor, mainly inhibits the growth and spread of tumor cells by inhibiting the activity of the PI3K/AKT signaling pathway, thereby exerting anti-cancer effects. The PI3K pathway is one of the key pathways for cell proliferation, survival and metabolism regulation, and excessive activation of PI3K is often closely related to the occurrence and progression of various tumors, especially in breast cancer, lung cancer, ovarian cancer and other malignant tumors. Abnormal activation of the PI3K pathway is considered to be an important mechanism for tumor cells to gain a growth advantage.

In the treatment of breast cancer, inalise is mainly targeted at patients who areHER2-negative and have abnormal activation of the PI3K pathway. Activation of the PI3K pathway can promote tumor cell proliferation, inhibit apoptosis, and enhance the invasiveness of tumor cells. Therefore, targeting the PI3K pathway has become an important therapeutic strategy.

Inaliset, as aPI3Kδ inhibitor, specifically targets the delta isoform of PI3K, which plays a key role in breast cancer cells. By inhibiting the activity of PI3Kδ isoform, inalisate can effectively slow down the proliferation of tumor cells and reduce tumor invasiveness and metastasis ability. At the same time, PI3Kδ inhibition can also restore the sensitivity of tumor cells to other treatments, especially resistance to chemotherapy and other targeted drugs.

The mechanism of action of inaliset also includes enhancing anti-tumor effects by regulating immune responses. The PI3K pathway not only plays a role in tumor cells, but also plays an important role in immune cells in the tumor microenvironment. By inhibiting the activity of PI3Kδ, inalisate can change the tumor microenvironment, promote the recognition and clearance of tumor cells by immune cells, and further enhance the anti-cancer effect.

In addition, inaliset can effectively slow down tumor growth and metastasis during treatment, especially for breast cancer patients who have become resistant to other treatments. By targeting the PI3K pathway, inalise offers a new treatment option, especially for patients with advanced and metastatic breast cancer, and offers new hope for patients.

Reference materials:https://www.itovebi-hcp.com/